Stem Cell Therapy for Lupus (SLE) in Istanbul, Turkey

Laboratory work, kidney and organ assessment, infusion monitoring and the number of sessions are itemized separately, and our patient coordination team states what the quote assumes about your current medication. If disease activity changes the plan, the revised figure is confirmed in writing before anything proceeds.

Those medicines continue under your rheumatologist. Our medical team reviews the full list before treatment because immune-modifying drugs affect infection risk, healing and timing, and shares the plan with your specialist so nothing is changed in isolation.

No - an active flare, new organ involvement or a rising antibody and protein picture means care where you are, promptly, rather than a flight. Our team reviews activity first and will ask you to stabilise with your rheumatologist before we plan anything. The case review itself can go ahead in the meantime.

Yes. Our regenerative medicine program works with mesenchymal stromal cells (MSCs) grown from Wharton's jelly, the gelatinous tissue inside the umbilical cord. It is donated after a healthy birth with written maternal consent, from tissue that would otherwise be discarded, so nothing is taken from mother or baby and none of the ethical questions attached to embryonic sources arise. Because these cells expand readily in culture, a batch is characterised and release-tested before it reaches anyone. Your written plan names the material, how it is prepared, the dose, the route of administration and the schedule, and our medical team explains why each of those was chosen for your case.

Wharton's jelly is a young, perinatal tissue rather than an adult one, so the starting material does not carry the age or the health history of the person being treated, and nothing has to be harvested from you on the day. These cells also have a low-immunogenicity profile, which is why this source is studied for use between unrelated people. Most of all, they are strong secretors: the signalling molecules MSCs release are the mechanism most current research centres on, and that is what a plan is built around.

The length of stay follows your plan: the route of administration, the number of sessions, the monitoring after each one, and any mobility or assistance you need. Our patient coordination team confirms appointment dates, daily timings and the expected length of the visit in writing before you book flights.

No medical procedure is free of risk. Our medical team screens for infection, bleeding risk, medication interactions and other contraindications before treatment, explains the risks specific to the route used in your plan, and monitors you during administration and afterwards. If something makes treatment unsafe for you, we say so instead of proceeding.

Goals are set with you and described as aims, not results. Regenerative medicine treatments are planned individually, responses vary between patients and no clinical outcome can be guaranteed. Your plan states what will be measured, when it will be reviewed, and how treatment sits alongside the care you already receive.

Send your confirmed diagnosis, recent reports and imaging, your current medication list, previous procedures and the goals that matter to you. Our medical team reviews them remotely and comes back with an assessment of whether treatment in Istanbul is appropriate for your case, and what the next step would be.